COLUMBIA, Md., May 2 /PRNewswire/ -- Cylex Incorporated, a life sciences company and leader in immune function testing, today announced a 74 percent increase in first quarter revenues in 2006 to $603,000, up from 2005’s first quarter revenues of $346,000. Clinical revenues alone increased 84 percent from 2005’s first quarter. In fact, clinical sales have grown 48 percent in the current six months compared to the previous six months.
Cylex Inc. also noted that its flagship product, ImmuKnow(TM), the first and only FDA-cleared cellular assay for measuring and managing the health of a patient’s immune system, has significantly expanded its customer base in the organ transplant market. The ImmuKnow(TM) assay is now being used in over 50 medical centers in the U.S. ImmuKnow(TM) has been integrated into the management of transplant recipients at medical centers that include the University of Pittsburgh, Cleveland Clinic, INTEGRIS Baptist Medical Center in Oklahoma City, Duke University, Cedars Sinai, Tampa General, and the University of Miami, among others. At INTEGRIS, which is ranked among the top 5 centers in liver transplant survival, ImmuKnow(TM) has been adopted as a standard of care, and improvements in patient outcomes have been documented.
In addition, the assay is offered in the major reference laboratories around the country, including Quest Diagnostics, the Mayo Clinic, the Laboratory Corporation of America (LabCorp), Viracor, and ARUP Laboratories. The product is also now distributed to customers in countries outside the U.S., including Spain, Israel and Taiwan.
As a result of its increased clinical use, ImmuKnow(TM) has received greater attention in peer-reviewed literature at scientific conferences. Recently, as well, ImmuKnow(TM) has been adopted in new drug clinical trials by a number of large, multinational pharmaceutical companies. Cylex is now initiating clinical trials in bone marrow transplant at leading medical institutions.
“Our outstanding performance in the first quarter of the new year is consistent with our projections for the year,” said Judith Britz, Ph.D., Chairman and CEO of Cylex Inc. “We are continuing to make enormous progress in the transplant arena, but are also furthering our penetration into additional markets, including infectious diseases and autoimmune disorders. We anticipate 2006 to be a breakthrough year for Cylex.”
Cylex Inc. also announced that Series C financing is underway.
About Cylex Incorporated
Cylex is a life science company and a leader in the development and manufacture of unique products that use the immune system for predicting and managing human health. It is the first and only company to offer a patent- protected, FDA-cleared cellular assay of immune system function, ImmuKnow(TM), which measures the vitality of a patient’s immune system from a single drop of blood.
The company’s products enable physicians to better manage and personalize the treatment of life-threatening diseases, such as HIV, HCV, cancer, autoimmune and other disorders, as well as total patient management within solid organ and bone marrow transplantation.
For further information, visit http://www.cylex.net.
ImmuKnow(TM) is currently being incorporated into patient protocols at leading U.S. hospitals and clinics. It is the only standardized cellular assay, easily performed in the lab, with quick and accurate results. By optimizing therapy, ImmuKnow(TM) helps the physician lower the cost of treatment and improve treatment outcome, reduce the side effects of drugs, and enhance the patient’s prospects for long-term quality of life.
Quest Diagnostics, the leading provider of diagnostic testing, information and services in the United States, now provides ImmuKnow(TM) testing through its network of clinical laboratories nationwide.
Media Contacts: David Kalson, RF|Binder Partners 212-994-7513 david.kalson@rfbinder.com Kirsten Plonner, RF|Binder Partners 212-994-7546 kirsten.plonner@rfbinder.com
Cylex Incorporated
CONTACT: David Kalson, RF Binder Partners, +1-212-994-7513,david.kalson@rfbinder.com or Kirsten Plonner, RF Binder Partners,+1-212-994-7546, kirsten.plonner@rfbinder.com
Web site: http://www.cylex.net/
